Ublituximab FDA approval date

The FDA approved Ublituximab (BRIUMVI) on 28 Dec 2022.

FDA approval date
28 Dec 2022

Drug identity checked against registry records

Also recorded as BRIUMVI; TG-1101

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304NCT02656303TGTXPhase 2Terminated2022-05-26Actual
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)NCT07673744TGTXPhase 2Recruiting2028-07-01Estimated
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabNCT05877963TGTXPhase 3Recruiting2027-01-21Estimated
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisNCT07220252TGTXPhase 2, Phase 3Recruiting2030-01-01Estimated
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaNCT02612311TGTXPhase 3Terminated2023-02-22Actual
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxNCT04016805TGTXPhase 2Terminated2022-05-22Actual
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaNCT03828448TGTXPhase 2Terminated2022-05-16Actual
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)NCT03801525TGTXPhase 2, Phase 3Terminated2022-12-20Actual
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633TGTXPhase 3Active not recruiting2026-10-31Estimated
An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisNCT04130997TGTXPhase 3Active not recruiting2032-05-31Estimated
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)NCT07503873TGTXPhase 2Recruiting2027-07-31Estimated
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaNCT07680946TGTXPhase 2Recruiting2028-12-12Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2022-12-28DayUblituximabTG Therapeutics, Inc. · TGTXFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761238", "applicant_as_listed_by_fda": "TG THERAPEUTICS, INC", "brand_names": ["BRIUMVI"], "active_ingredients": ["UBLITUXIMAB-XIIY"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20221228", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026